ViewRay, Inc. (NASDAQ:VRAY) Director Purchases 16,000 Shares

ViewRay, Inc. (NASDAQ:VRAYGet Rating) Director Brian K. Roberts bought 16,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The shares were acquired at an average price of $2.98 per share, for a total transaction of $47,680.00. Following the completion of the transaction, the director now owns 147,761 shares in the company, valued at $440,327.78. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

VRAY traded down $0.05 during mid-day trading on Thursday, reaching $2.88. 1,380,460 shares of the stock were exchanged, compared to its average volume of 1,641,360. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.84 and a current ratio of 3.17. The stock has a market capitalization of $519.72 million, a PE ratio of -4.50 and a beta of 1.12. The company has a 50 day moving average price of $3.41 and a two-hundred day moving average price of $4.49. ViewRay, Inc. has a 1 year low of $2.39 and a 1 year high of $8.25.

ViewRay (NASDAQ:VRAYGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $18.88 million for the quarter, compared to the consensus estimate of $15.62 million. ViewRay had a negative net margin of 148.47% and a negative return on equity of 76.00%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.17) EPS. Sell-side analysts expect that ViewRay, Inc. will post -0.6 EPS for the current fiscal year.

Several equities research analysts recently commented on VRAY shares. Stifel Nicolaus started coverage on shares of ViewRay in a research report on Tuesday, January 25th. They set a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research upgraded shares of ViewRay from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Wednesday, May 11th. Piper Sandler cut their target price on shares of ViewRay from $9.00 to $7.00 in a research report on Friday, May 6th. Finally, StockNews.com initiated coverage on shares of ViewRay in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, ViewRay presently has an average rating of “Buy” and a consensus target price of $5.94.

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Hong Kong Ltd purchased a new position in ViewRay during the 3rd quarter worth $42,000. Baird Financial Group Inc. purchased a new position in shares of ViewRay in the 1st quarter worth about $42,000. Jupiter Asset Management Ltd. purchased a new position in shares of ViewRay in the 1st quarter worth about $48,000. MQS Management LLC purchased a new position in shares of ViewRay in the 1st quarter worth about $55,000. Finally, LPL Financial LLC purchased a new position in shares of ViewRay in the 4th quarter worth about $58,000. 86.04% of the stock is currently owned by hedge funds and other institutional investors.

About ViewRay (Get Rating)

ViewRay, Inc designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.

Featured Articles

Insider Buying and Selling by Quarter for ViewRay (NASDAQ:VRAY)

Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.